- Home
- MTCH vs ALKS Comparison
MTCH vs ALKS Comparison
Compare MTCH & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTCH | ALKS |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.7B |
| IPO Year | 2004 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MTCH | ALKS |
|---|---|---|
| Price | $41.48 | $40.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 19 |
| Target Price | $41.88 | ★ $56.28 |
| AVG Volume (30 Days) | ★ 3.1M | 2.3M |
| Earning Date | 11-03-2026 | 10-27-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 17.82 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $3,487,197,000.00 | $1,475,899,000.00 |
| Revenue This Year | N/A | $23.54 |
| Revenue Next Year | $3.97 | $6.53 |
| P/E Ratio | $30.15 | ★ N/A |
| Revenue Growth | ★ 0.22 | N/A |
| 52 Week Low | $28.81 | $27.00 |
| 52 Week High | $44.94 | $55.67 |
Technical Indicators
Market Signals| Indicator | MTCH | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 34.95 |
| Support Level | $39.61 | $39.84 |
| Resistance Level | $42.98 | $43.22 |
| Average True Range (ATR) | 1.01 | 1.23 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 64.61 | 24.03 |
Price Performance
Historical ComparisonAbout MTCH Match Group Inc.
Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. It generates the majority of its revenue from the Tinder segment.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.